Professional DDS developing company -Anxo Pharmaceutical Company (ANXO, stock code: 6677) today (26th Feb.) announced that, first milestone payment from Guangzhou HC Company has been received, and which also indicated that Co-development Agreement on 3 products has been formally moved forward. This Cooperation Agreement contains upfront payment for product development, milestone payment and royalty, about 30 million RMB in total. Until this moment, ANXO has signed 18 product-development agreements with 6 China companies, and this year, these efforts on investing China Generic Quality Consistency Evaluation (GQCE) start to pay off.